Tissue factor (TF) is the lipoprotein cofactor for blood coagulation factor VIIa. It is essential for initiation of the """"""""extrinsic"""""""" pathway of coagulation and, in addition, may play a critical role in """"""""intrinsic"""""""" coagulation as well. Cellular expression of TF has been implicated in the thromboembolic complications which occur """"""""idiopathically"""""""" and those associated with infectious, inflammatory, and neoplastic disorders. Small quantities of highly purified human TF have already been isolated in our laboratory. We propose the large scale purification of human TF apoprotein and its biochemical characterization. Specific polyclonal and monoclonal anti-TF antibodies will be raised and immunoassays for TF development. These tools will be used to study the in vitro synthesis of TF by cultured cells focusing on the possible presence of inactive, precursor forms of TF, the determination of the intracellular location of TF, and the mechanism of TF transfer to the cell surface. Normal plasma contains an inhibitor of TF activity which likely plays an important physiological role in the regulation of in vivo hemostasis and may explain the clinical requirement for an intact """"""""intrinsic"""""""" coagulation pathway (i.e., the presence of factors VIII and IX). This TF inhibitor will be purified and characterized and its mode of action determined. Polyclonal and monoclonal anti-inhibitor antibodies will be raised and used to construct immunoassays for the TF inhibitor in plasma. Functional and immunoassays for both TF and TF inhibitor will be used to detect their levels in blood from normals and patients with specific disease states. In particular, studies will be performed to assess the interrelationship between TF and TF inhibitor levels in thromboembolic disease. Finally, the location of TF in normal and pathologic tissues will be determined using immuno-histochemical or immuno-fluorescent techniques with specific reference to comparing normal and atherosclerotic vessels. These studies are designed to provide information, now lacking, concerning the initiation and control of coagulation at the TF level and the interrelationship between the classical """"""""extrinsic"""""""" and """"""""intrinsic"""""""" coagulation pathways in vivo. The results should enhance our understanding of normal hemostasis and pathologic thromboembolism.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034462-03
Application #
3347373
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1985-07-01
Project End
1988-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Ndonwi, M; Broze Jr, G (2008) Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 6:1044-6
Ndonwi, Matthew; Broze Jr, George J; Agah, Sayeh et al. (2007) Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX. J Biol Chem 282:15632-44
Ndonwi, M; Broze Jr, G; Bajaj, S P (2005) The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII--tissue factor complex. J Thromb Haemost 3:112-8
Lu, Genmin; Broze Jr, George J; Krishnaswamy, Sriram (2004) Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem 279:17241-9
Forastiero, R R; Martinuzzo, M E; De Larranaga, G et al. (2003) Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. J Thromb Haemost 1:2250-1
Forastiero, R R; Martinuzzo, M E; Broze, G J (2003) High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 1:718-24
Forastiero, R R; Martinuzzo, M E; Lu, L et al. (2003) Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 1:1764-70
Eitzman, Daniel T; Westrick, Randal J; Bi, Xiaoming et al. (2002) Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 105:2139-42
Westrick, R J; Bodary, P F; Xu, Z et al. (2001) Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103:3044-6
Chan, J C; Carmeliet, P; Moons, L et al. (1999) Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 103:475-82

Showing the most recent 10 out of 47 publications